Literature DB >> 7412778

Measurement of acetylcholine receptor and anti-receptor antibodies by ELISA.

N L Norcross, I J Griffith, J A Lettieri.   

Abstract

Both acetylcholine receptor (AChR) and antibodies capable of binding to the AChR can be measured using the recently developed enzyme-linked immunosorbent assay (ELISA). The assay is very sensitive and reproducible. Because of the relative simplicity of the ELISA in comparison to radioimmunoassay procedures currently used to measure anti-AChR antibodies, the ELISA may prove valuable as a clinical diagnostic tool for the human disease myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7412778     DOI: 10.1002/mus.880030412

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

1.  In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor.

Authors:  M K Waldor; S Sriram; H O McDevitt; L Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

2.  The relation of clinical disease to antibody titre, proliferative response and neurophysiology in murine experimental autoimmune myasthenia gravis.

Authors:  A R Pachner; F S Kantor
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

3.  Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies.

Authors:  V A Lennon; D J McCormick; E H Lambert; G E Griesmann; M Z Atassi
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

4.  Anti-idiotypic route to anti-acetylcholine receptor antibodies and experimental myasthenia gravis.

Authors:  N H Wassermann; A S Penn; P I Freimuth; N Treptow; S Wentzel; W L Cleveland; B F Erlanger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.